ATAI vs AXSM
ATAI: Atai Beckley is a clinical-stage biotech firm developing novel treatments for central nervous system disorders. AXSM: A biopharmaceutical company developing and commercializing innovative therapies for central nervous system disorders.
Side-by-side fundamentals
| Metric | ATAI | AXSM | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $7.38 | $205.40 | |
| Market cap as of 2026-08-25 | $2.7B | $10.8B | |
| PEG as of 2026-08-25 | n/a | 1.94 | |
| Net margin as of 2026-08-25 | -19019.4% | -24.7% | AXSM higher |
| Gross margin as of 2026-08-25 | n/a | +93.2% | |
| Operating margin as of 2026-08-25 | -18569.1% | -24.0% | AXSM higher |
| ROE as of 2026-08-25 | -366.5% | -255.6% | AXSM higher |
| ROA as of 2026-08-25 | -269.0% | -27.1% | AXSM higher |
| Debt / equity as of 2026-08-25 | 0.00 | 2.43 | ATAI lower |
| Revenue growth (YoY) as of 2026-08-25 | +86.7% | +56.9% | ATAI higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +133.7% | |
| Beta as of 2026-08-25 | 1.59 | 0.86 | |
| 1-year return as of 2026-08-24 close | +61.5% | +73.3% | AXSM higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.